Systemic therapy for patients with advanced, unresectable or metastatic renal cell carcinoma: moving to guidelines

Abstract

Until recently, patients with advanced, unresectable or metastatic renal cell cancer (RCC) had very few therapeutic options. Cytokine therapy, consistingmainly of interferon-a and interleukin-2, was considered the mainstay of therapy. A better understanding of the biology of RCC has led to the development of novel therapeutic agents that target angiogenesis. Inactivation of thevon Hippel-Lindau tumour-suppressor gene VHL, which is present in …

Authors

Hotte SJ; Kapoor AK

Journal

Canadian Urological Association Journal, Vol. 1, No. 2S,

Publisher

Canadian Urological Association Journal

DOI

10.5489/cuaj.66

Associated Experts

Sebastien Hotte

Professor, Faculty of Health Sciences

Visit profile

Labels

Fields of Research (FoR)

3202 Clinical sciences 3211 Oncology and carcinogenesis

View published work (Non-McMaster Users)